在静脉输液中使用在线过滤器去除纤维材料可以追溯到1830年代初。随着治疗干预措施的进步,高容量液体支持和非肠道给药的药物和生物制剂,一些观察家呼吁常规使用床边过滤。不幸的是,过滤器组件的评估,它们与药物产品的相互作用和相容性,使用对临床结果的影响不能由单个实体进行。使用建议通常基于零散和不完整的信息。当前在评估使用在线过滤器的收益/风险概况方面的挑战不容忽视。虽然有一些实例显示明确的治疗设置,其中静脉输液的在线过滤可能会提供额外的安全边际,因此,净收益,迄今为止,大多数观察性研究未能为广泛的常规使用提供足够的科学支持。虽然输液器过滤器在专家意见得到科学证据充分证实的情况下是合适的,在肠胃外给药期间使用的过滤器的一般和常规使用不能得到实质性研究的支持,因此不应常规使用.最终,决定权落在医疗服务提供者与现有的信息。
The use of in-line filters to remove fibrous material in the administration of intravenous fluids dates to the early 1830\'s. Following advancements in therapeutic interventions, high volume fluid support and parenterally administered drugs and biologic preparations, some observers are calling for a routine use of bedside filtration. Unfortunately, the assessment of filter components, their interaction and compatibility with the drug product, and the impact of use on clinical outcomes cannot be conducted by a single entity. Recommendations for use are often predicated upon fragmented and incomplete information. The current challenges in evaluating the benefit/risk profile for the use of in-line filters should not be ignored. While there are select instances showing well-defined therapeutic settings where in-line filtration of intravenous infusions would likely provide an additional safety margin and hence, net benefit, the majority of observational studies to date fail to provide sufficient scientific support for broad-based routine use. While infusion set filters are appropriate where expert opinion is well corroborated by scientific evidence, the general and routine use of filters used during parenteral administration cannot be supported by substantive studies and should not be routinely utilized. Ultimately, the determination falls to a healthcare provider with the information available at-hand.